跳至主要内容
临床试验/NCT00250458
NCT00250458已完成3 期

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated With Rizatriptan Orally Disintegrating Tablet (ODT)

Organon and Co0 个研究点目标入组 346 人开始时间: 2006年3月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
346
主要终点
Participants With Elimination of Nausea at 2 Hours Postdose

研究概览

简要总结

Study to test the effectiveness of a marketed drug in the treatment of migraine-associated nausea.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 6-month history of migraine, moderate to severe migraine attacks with nausea, 1-6 migraine attacks per month

排除标准

  • Heart disease, high blood pressure

结局指标

主要结局

Participants With Elimination of Nausea at 2 Hours Postdose

时间窗: At 2 hours after treatment

Participants reporting the absence of nausea at 2 hours post treatment. Absence or presence of nausea was recorded by the participants in an electronic diary. Absence is defined as no nausea at 2 hours post-treatment.

次要结局

  • Participants With Pain Relief at 2 Hours Postdose(2 hours after treatment)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验